RESUMO
No disponible
Assuntos
Humanos , Feminino , Adulto , Meningioma/secundário , Meningioma/complicações , Doenças do Nervo Trigêmeo/etiologia , Neoplasias Meníngeas/complicações , Neoplasias Meníngeas/diagnóstico , Recidiva Local de Neoplasia , Olho/patologia , Tacrolimo/administração & dosagem , Curativos Hidrocoloides , Úlcera/etiologiaRESUMO
No disponible
Assuntos
Humanos , Feminino , Criança , Síndrome de Ehlers-Danlos/diagnóstico por imagem , Hematoma/diagnóstico por imagem , Hematoma/patologia , Instabilidade Articular/complicações , Eletrocardiografia , Extremidade Inferior/patologia , Diagnóstico DiferencialAssuntos
Ciclosporina/farmacocinética , Ciclosporina/uso terapêutico , Imunossupressores/farmacocinética , Imunossupressores/uso terapêutico , Psoríase/tratamento farmacológico , Administração Oral , Adulto , Ciclosporina/sangue , Monitoramento de Medicamentos , Feminino , Humanos , Imunossupressores/sangue , Masculino , Memória Episódica , Psoríase/sangue , Índice de Gravidade de DoençaAssuntos
Linfoma Folicular/genética , Linfoma Folicular/patologia , Linfoma Difuso de Grandes Células B/genética , Linfoma Difuso de Grandes Células B/patologia , Neoplasias Primárias Múltiplas/genética , Neoplasias Primárias Múltiplas/patologia , Idoso de 80 Anos ou mais , Transformação Celular Neoplásica/genética , Transformação Celular Neoplásica/patologia , Evolução Fatal , Humanos , Neoplasias do Jejuno/genética , Neoplasias do Jejuno/patologia , Masculino , Proteínas Proto-Oncogênicas c-bcl-2/genética , Proteínas Proto-Oncogênicas c-bcl-6/genética , Proteínas Proto-Oncogênicas c-myc/genética , Neoplasias Cutâneas/genética , Neoplasias Cutâneas/patologiaRESUMO
INTRODUCCIÓN: La urticaria solar (US) es una fotodermatosis infrecuente. Los antihistamínicos constituyen la primera línea de tratamiento, incluyéndose en segunda línea la inducción de fototolerancia mediante fototerapia con ultravioleta. OBJETIVOS: Describir y evaluar la eficacia de un protocolo de desensibilización, con UVB de banda estrecha (UVB-BE) en pacientes con US. MATERIAL Y MÉTODOS: Estudio retrospectivo de pacientes diagnosticados de US con espectro de acción en UVA, luz visible (LV) o ambas, que habían realizado fototerapia con UVB-BE para inducir fototolerancia. Se realizan cursos cortos (menos de 20 sesiones, 3 por semana) durante la primavera, con dosis inicial determinada por el fototipo. Se recogen resultados del Skindex-29 antes del tratamiento y después del verano, y un cuestionario no validado de efectividad terapéutica después del verano para valorar actividad de la enfermedad y grado de satisfacción. RESULTADOS: Se incluyen 8 pacientes con espectro de acción: 50% LV y 50% UVA más luz visible. Se realizaron 17 cursos anuales (1-6 cursos por paciente), de 11 a 20 sesiones. La dosis media de UVB-BE por curso fue 7,45J/cm2. Ningún paciente presentó brotes o efectos adversos durante el tratamiento. La respuesta fue satisfactoria en 6 pacientes. En el 78,6% de los tratamientos la mejoría en el Skindex-29 global fue superior al 20%. La mejoría en las subescalas sintomática y funcional fue superior al 20% en el 71% y el 64% respectivamente. CONCLUSIÓN: La inducción de fototolerancia con UVB-BE en la US es un procedimiento seguro y efectivo en un elevado porcentaje de pacientes
INTRODUCTION: Solar urticaria is an uncommon photodermatosis. First-line treatment is with antihistamines; second-line treatment includes induction of light tolerance using UV phototherapy. OBJECTIVES: We aimed to describe and evaluate the effectiveness of a desensitization protocol with narrowband UV-B in patients with solar urticaria. MATERIAL AND METHODS: We performed a retrospective study of patients with solar urticaria with an action spectrum in the UV-A range, the visible light range, or both who had received therapy with narrowband UV-B for induction of light tolerance. Short courses of treatment were administered (< 20 sessions, 3 per week) during spring. The initial dose was determined according to the skin type. The Skindex-29 was administered before treatment and after summer; a nonvalidated questionnaire was also administered after summer to evaluate disease activity and satisfaction with treatment. RESULTS: We included 8 patients with an action spectrum (4 with visible light and 4 with UVA plus visible light). Seventeen courses (1-6 per patient) were administered per year. The number of sessions per year ranged from 11 to 20. The mean dose of narrowband UV-B per course was 7.45J/cm2. No patients experienced flares or adverse effects during treatment. The response was satisfactory in 6 patients. The improvement in the overall Skindex-29 score was greater than 20% in 78.6% of cases. The improvement in the function and symptoms subscales was over 20% in 71% and 64% of cases, respectively. CONCLUSION: Induction of light tolerance with narrowband UV-B in solar urticaria is safe and effective in a high percentage of patients
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Dermatopatias/terapia , Urticária/terapia , Fototerapia , Terapia Ultravioleta/métodos , Estudos Retrospectivos , Inquéritos e QuestionáriosRESUMO
No disponible
Assuntos
Humanos , Feminino , Pessoa de Meia-Idade , Calcinose/diagnóstico por imagem , Dermatomiosite/complicações , Neoplasias da Mama , Neoplasias de Tecidos Moles/complicações , Calcinose/complicações , Face/diagnóstico por imagem , Face/patologia , Carcinoma Ductal de Mama/secundárioRESUMO
INTRODUCTION: Solar urticaria is an uncommon photodermatosis. First-line treatment is with antihistamines; second-line treatment includes induction of light tolerance using UV phototherapy. OBJECTIVES: We aimed to describe and evaluate the effectiveness of a desensitization protocol with narrowband UV-B in patients with solar urticaria. MATERIAL AND METHODS: We performed a retrospective study of patients with solar urticaria with an action spectrum in the UV-A range, the visible light range, or both who had received therapy with narrowband UV-B for induction of light tolerance. Short courses of treatment were administered (<20 sessions, 3 per week) during spring. The initial dose was determined according to the skin type. The Skindex-29 was administered before treatment and after summer; a nonvalidated questionnaire was also administered after summer to evaluate disease activity and satisfaction with treatment. RESULTS: We included 8 patients with an action spectrum (4 with visible light and 4 with UVA plus visible light). Seventeen courses (1-6 per patient) were administered per year. The number of sessions per year ranged from 11 to 20. The mean dose of narrowband UV-B per course was 7.45J/cm2. No patients experienced flares or adverse effects during treatment. The response was satisfactory in 6 patients. The improvement in the overall Skindex-29 score was greater than 20% in 78.6% of cases. The improvement in the function and symptoms subscales was over 20% in 71% and 64% of cases, respectively. CONCLUSION: Induction of light tolerance with narrowband UV-B in solar urticaria is safe and effective in a high percentage of patients.
